|
| |
Phenomix CorporationPhenomix is a drug discovery and development company with a portfolio of therapeutic programs underway in immune disease and metabolic syndrome. By generating detailed physiological data in a mammalian system, Phenomix creates biological insight that allows earlier and better informed decisions across the discovery and development process.
Phenomix’ approach is based on the observation that incorporating detailed in vivo studies early into the discovery process drives more informed decisions and reduces late stage failures. The Company has integrated effective phenotyping assays and disease models into all stages of the drug discovery and development process. The platform is further complemented by expertise in drug discovery, medicinal chemistry, translational medicine and clinical development. Phenomix’ lead program for treatment of type 2 diabetes will be in Phase II of clinical development in 2006.
| Contact Details: |
| 5871 Oberlin DriveSuite 200 |
| San Diego |
| California |
| 92121 |
| United States of America |
| Tel: | 1.858.731.5200 |
| Fax: | 1.858.731.5225 |
| Email: | info@phenomix.com |
| WWW: | www.phenomixcorp.com/
|
|
Loading...
|
Recent Publications by Phenomix Corporation: |  |
Synthesis and antiviral activity of HCV NS3/4A peptidomimetic boronic acid inhibitors.
A new series of NS3/4A protease boronic acid inhibitors is described. The... | 29th August, 2009
| Phenomix Corporation, 5930 Cornerstone Court West, Suite 230, San Diego,
| Bioorg Med Chem Lett. 2009 Oct 1;19(19):5708-11. Epub 2009 Aug 8.
DOI Direct Link |
Bicyclic cyanothiazolidines as novel dipeptidyl peptidase 4 inhibitors.
The synthesis and biochemical evaluation of novel cyanothiazolidine... | 2nd June, 2009
| Phenomix Corporation, 5871 Oberlin Drive, Suite 200, San Diego, CA 92121,
| Bioorg Med Chem Lett. 2009 Aug 1;19(15):4437-40. Epub 2009 May 18.
DOI Direct Link |
Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects.
BACKGROUND: PHX1149 is a dipeptidyl peptidase-4 (DPP4) inhibitor that is... | 7th December, 2007
| Phenomix Corporation, San Diego, California 92121, USA.
| Clin Ther. 2007 Aug;29(8):1692-705.
DOI Direct Link |
ENU-mutagenesis: insight into immune function and pathology.
In random chemical mutagenesis, gene discovery is driven by phenotypes... | 6th February, 2007
| Frank Fenner Building, Australian National University, Canberra ACT 0200,
| Curr Opin Immunol. 2006 Oct;18(5):627-33. Epub 2006 Aug 4.
DOI Direct Link |
Press Releases on Phenomix Corporation:
|
 |
| 2009 Pharma ChemOutsourcing Show Attendance Up an Astounding 60% Despite Current Recession |
3rd June, 2009 |
Apaporis LLC |
LONG BRANCH, N.J., June 3 /PRNewswire/ -- The 2009 Pharma ChemOutsourcing Conference & Exhibition attendance is way up again in 2009 and is poised to shatter the attendance record set in 2008.
|
| Forest Laboratories, Inc. Reports Fiscal Year 2009 Fourth Quarter Reported EPS of $0.31 Including $0.45 Per Share Charge Related to the Ongoing United States Attorney's Office Investigation |
21st April, 2009 |
Forest Laboratories, Inc. |
Company Provides Fiscal Year 2010 EPS Guidance in the Range of $3.45-$3.55 Per Share
NEW YORK, April 21 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX), a U.S.-based pharmaceutical
|
| Forest Laboratories, Inc. Reports Q3'09 Diluted Earnings Per Share of $0.62, Including $0.41 Per Share Charge for New Product Licensing Fees |
20th January, 2009 |
Forest Laboratories, Inc. |
NEW YORK, Jan. 20, 2009 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX), a U.S. based pharmaceutical company, today announced that reported diluted earnings per share equaled $0.62 in
|
| Phenomix and Forest Laboratories to Collaborate on Development and Commercialization of Dutogliptin in Diabetes |
23rd October, 2008 |
Forest Laboratories, Inc. |
NEW YORK and SAN DIEGO, Oct. 23, 2008 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX) and Phenomix Corporation today announced that they have entered into a definitive collaboration
|
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 413 times since April 2007, the link to the organisation's website has been followed 62 times Recent Search Terms used to find this page: Bicyclic cyanothiazolidines as novel dipeptidyl peptidase 4 inhibitors | Phenomix Corporation location | phenomix and conference | nyse phenomix | phenomix USA | phenomi | phenomix corporation | Forest Laboratories translational medicine | . Search for more companies in San Diego Search for more companies in California This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Phenomix Corporation |
